Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.

Spivak JL.

Ann Intern Med. 2010 Mar 2;152(5):300-6. doi: 10.7326/0003-4819-152-5-201003020-00008. Review.

PMID:
20194236
2.
4.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.

Orv Hetil. 2006 Nov 12;147(45):2175-9. Hungarian.

PMID:
17402211
5.

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.

N Engl J Med. 2005 Apr 28;352(17):1779-90.

6.

[New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].

Larsen TS, Pallisgaard N, Christensen JH, Gram-Hansen P, Kerndrup GB, Møller MB, Hasselbalch HC.

Ugeskr Laeger. 2006 Sep 25;168(39):3299-303. Review. Danish.

PMID:
17032592
7.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Eur J Haematol. 2007 Dec;79(6):508-15. Epub 2007 Oct 23.

PMID:
17961178
8.

Polycythemia vera: scientific advances and current practice.

Tefferi A, Spivak JL.

Semin Hematol. 2005 Oct;42(4):206-20. Review.

PMID:
16210034
9.

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.

Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC.

Mod Pathol. 2007 Sep;20(9):929-35. Epub 2007 Jul 20.

10.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
11.

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR.

Haematologica. 2011 Oct;96(10):1462-9. doi: 10.3324/haematol.2011.045591. Epub 2011 Jun 28.

12.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
13.

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Tefferi A, Barbui T.

Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895. Review. Erratum in: Am J Hematol. 2015 Sep;90(9):849.

14.

Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Leukemia. 2008 Jan;22(1):194-5. Epub 2007 Jul 12. No abstract available.

PMID:
17625603
15.

Characterization of murine JAK2V617F-positive myeloproliferative disease.

Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW.

Cancer Res. 2006 Dec 1;66(23):11156-65.

16.

Familial chronic myeloproliferative disorders: the state of the art.

Rumi E.

Hematol Oncol. 2008 Sep;26(3):131-8. doi: 10.1002/hon.863. Review.

PMID:
18484677
17.

Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.

Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR.

Exp Hematol. 2007 Nov;35(11):1641-6. Epub 2007 Oct 17.

18.

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA.

PLoS One. 2006 Dec 20;1:e18.

19.

JAK2 inhibitors: not the next imatinib but researchers see other possibilities.

Garber K.

J Natl Cancer Inst. 2009 Jul 15;101(14):980-2. doi: 10.1093/jnci/djp216. Epub 2009 Jul 7. No abstract available.

PMID:
19584324
20.

Supplemental Content

Support Center